Literature DB >> 12700338

Endogenous cholesterol synthesis is associated with VLDL-2 apoB-100 production in healthy humans.

Berthil H C M T Prinsen1, Johannes A Romijn, Peter H Bisschop, Martina M J de Barse, P Hugh R Barrett, Mariëtte Ackermans, Ruud Berger, Ton J Rabelink, Monique G M de Sain-van der Velden.   

Abstract

Subjects with high plasma cholesterol levels exhibit a high production of VLDL apolipoprotein B-100 (apoB-100), suggesting that cholesterol is a mediator for VLDL production. The objective of the study was to examine whether endogenous cholesterol synthesis, reflected by the lathosterol-cholesterol ratio (L-C ratio), affects the secretory rates of different VLDL subfractions. Ten healthy subjects were studied after overnight fasting. During a 10 h primed, constant infusion of 13C-valine (15 micromol/kg/h), enrichment was determined in apoB-100 from ultracentrifugally isolated VLDL-1 and VLDL-2 by gas chromatography mass spectrometry. The synthesis rates of VLDL-1 apoB-100 and VLDL-2 apoB-100, catabolism, and transfer were estimated by compartmental analysis. Mean VLDL-1 apoB-100 pool size was 90 +/- 15 mg, and mean VLDL-2 apoB-100 pool size was 111 +/- 14 mg. Absolute synthesis rate of VLDL-1 apoB-100 was 649 +/- 127 mg/day and 353 +/- 59 mg/day for VLDL-2 apoB-100. There was a strong association between the absolute synthesis rate of VLDL-2 apoB-100 and L-C ratio (r 2 = 0.61, P < 0.01). In contrast, no correlation was observed between L-C ratio and absolute synthesis rate of VLDL-1 apoB-100 (r 2 = 0.302, P = 0.09). In conclusion, these data provide additional support for an independent regulation of VLDL-1 apoB-100 and VLDL-2 apoB-100 production. Endogenous cholesterol synthesis is correlated only with the VLDL-2 apoB-100 production.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12700338     DOI: 10.1194/jlr.M300023-JLR200

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  6 in total

Review 1.  Pathophysiology of dyslipidaemia in the metabolic syndrome.

Authors:  G D Kolovou; K K Anagnostopoulou; D V Cokkinos
Journal:  Postgrad Med J       Date:  2005-06       Impact factor: 2.401

2.  Metabolism of Triglyceride-Rich Lipoproteins.

Authors:  Jan Borén; Marja-Riitta Taskinen
Journal:  Handb Exp Pharmacol       Date:  2022

Review 3.  Metabolism of triglyceride-rich lipoproteins in health and dyslipidaemia.

Authors:  Jan Borén; Marja-Riitta Taskinen; Elias Björnson; Chris J Packard
Journal:  Nat Rev Cardiol       Date:  2022-03-22       Impact factor: 49.421

4.  Levels of high-density lipoprotein cholesterol (HDL-C) among children with steady-state sickle cell disease.

Authors:  Magda O Seixas; Larissa C Rocha; Mauricio B Carvalho; Joelma F Menezes; Isa M Lyra; Valma M L Nascimento; Ricardo D Couto; Ájax M Atta; Mitermayer G Reis; Marilda S Goncalves
Journal:  Lipids Health Dis       Date:  2010-08-27       Impact factor: 3.876

Review 5.  Fatty liver, insulin resistance, and dyslipidemia.

Authors:  Martin Adiels; Marja-Riitta Taskinen; Jan Borén
Journal:  Curr Diab Rep       Date:  2008-02       Impact factor: 4.810

6.  Integrative analyses of hepatic differentially expressed genes and blood biomarkers during the peripartal period between dairy cows overfed or restricted-fed energy prepartum.

Authors:  Khuram Shahzad; Massimo Bionaz; Erminio Trevisi; Giuseppe Bertoni; Sandra L Rodriguez-Zas; Juan J Loor
Journal:  PLoS One       Date:  2014-06-10       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.